CommercialCoverageLow impact
Gene Expression Profiling for Uveal Melanoma
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Ophthalmology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for gene expression profiling for uveal melanoma, confirming that DecisionDx-UM testing is medically necessary for primary, localized uveal melanoma cases. All other gene expression profiling for uveal melanoma remains investigational and non-covered.
Action Required
Immediately: Review any pending or future uveal melanoma gene expression profiling claims to ensure they meet the medically necessary criteria (primary, localized uveal melanoma using DecisionDx-UM test). Billing team should verify test type and tumor classification before submitting claims to avoid denials for investigational services.